1 The effects of papaverine on coronary blood flow, myocardial oxygen consumption, myocardial oxygen tension and the ischaemic ECG pattern were studied in anaesthetized open-chest cats representing three models of acute coronary insufficiency: ligation, spasm, and perfusion of the coronary artery at a stabilized insufficient level. 2 Despite the increase in myocardial oxygen consumption reflecting elevation of oxygen demand, papaverine improved the signs of myocardial ischaemia (the myocardial oxygen tension and ECG pattern), as long as there was a possibility of an increase in blood supply to the affected zone. Where this was excluded, the symptoms were actually aggravated. 3 The results suggest that there is no basis for dividing coronary dilators into 'benign' and 'malignant' according to their ability to increase myocardial oxygen requirements. A coronary dilator enhancing oxygen demand may prove beneficial even following complete coronary artery occlusion.
1The effects of chloracyzine (2-chloro-10-(3-diethylaminopropionyl)-phenothiazine hydrochloride; antianginal drug) on myocardial oxygen consumption were studied in open-chest cats and cat isolated hearts using oximetry and polarography respectively. 2 It was found that chloracyzine produced a decrease in myocardial oxygen consumption accompanied by a reduction in coronary blood flow preceded by transient coronary dilatation. Chloracyzine produced an insignificant increase in arterial pressure; heart rate increased slightly in the open-chest experiments but not in the isolated heart. 3 It is suggested that reduced oxygen uptake after chloracyzine is realized through improved efficiency in the use of oxygen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.